There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) and Xeris Pharmaceuticals (XERS – Research Report) with bullish sentiments.
Oric Pharmaceuticals (ORIC)
Oric Pharmaceuticals received a Buy rating and a $12.00 price target from Wedbush analyst David Nierengarten on January 2. The company’s shares closed last Wednesday at $8.97, close to its 52-week high of $9.79.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
Oric Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.67.
See Insiders’ Hot Stocks on TipRanks >>
Xeris Pharmaceuticals (XERS)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xeris Pharmaceuticals, with a price target of $51.00. The company’s shares closed last Wednesday at $2.24.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $16.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ORIC:
- ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Oric Pharmaceuticals files to sell 12.14M shares of common stock for holders
- Oric Pharmaceuticals price target lowered by $1 at H.C. Wainwright, here’s why
- Oric Pharmaceuticals price target lowered by $2 at Wedbush, here’s why
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
